TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03289936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNIPPV
Description: Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNIPPV
Description: Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
Study: NCT03171844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin
Description: 3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
Study: NCT03399981

Intervention type: BIOLOGICAL
Intervention: Tysabri
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Intervention: Tysabri
Description: Administered as specified in the treatment arm.
Study: NCT01713842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCZ
Description: Tocilizumab at week 0, 4 and 8.
Study: NCT00314626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: Efavirenz

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir+lamivudine
Description: Abacavir+lamivudine
Study: NCT03819062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: A 3 week treatment period with 8 treatment sessions in total.
Study: NCT03211221

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies \< or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (\> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies \< or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (\> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
Study: NCT03714321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MIE)
Description: Randomization of 30 patients, 15 in each arm, to receive either CPAP or MIE.
Study: NCT00955812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-31121
Description: 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
Study: NCT03174418

Intervention type: PROCEDURE
Intervention: Coronary angiography and optical coherence tomography
Description: Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level

Intervention type: PROCEDURE
Intervention: Coronary angiography and optical coherence tomography
Description: Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
Study: NCT03821818

Intervention type: BEHAVIORAL
Intervention: Food Allergy Elimination + Willis Exercise
Description: Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise \> 75% max heart rate, 5/day)
Study: NCT03347981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of hydrophobic material

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator
Description: Implantation of trifocal IOL POD F consisting of hydrophilic material
Study: NCT03179891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film 12.5 mg
Description: All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film 12.5 mg
Description: All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
Study: NCT01512602

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DBT
Description: 16 weeks DBT treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAMS
Description: CAMS-informed psychotherapy
Study: NCT05805943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM0306
Description: IMM0306 is an bi-specific antibody
Study: NCT03487809

Intervention type: DRUG
Intervention: Budesonide/Cisclesonide
Description: One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older

Intervention type: DRUG
Intervention: Budesonide/Cisclesonide
Description: One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older

Intervention type: DRUG
Intervention: Budesonide/Cisclesonide
Description: One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
Study: NCT02607592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin and pemetrexed
Description: cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin+pemetrexed
Description: nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
Study: NCT03198520

Intervention type: DEVICE
Group type: OTHER
Intervention: Solvay Dental 360™
Description: polymer Removable Partial Denture (RPD)
Study: NCT01688128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase I U-SMART (4 wks)
Description: Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout (2 wks)
Description: 2-weeks wash out period in both arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout (2 wks)
Description: 2-weeks wash out period in both arms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase II U-SMART (4 wks)
Description: Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
Study: NCT01141114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study: NCT00761852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruboxistaurin
Description: 32 mg daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab po QD for 2 weeks
Study: NCT04095780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene care programme
Description: 1. Brush teeth with standardized power tooth brush twice a day.~2. Rinse mouth with chlorhexidine twice a day.~3. Oral hygiene education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction
Description: Oral hygiene education
Study: NCT04431336

Intervention type: BEHAVIORAL
Intervention: movement
Description: movement
Study: NCT03076931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microlaryngoscopy
Description: Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microlaryngoscopy
Description: Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voice Evaluation
Description: Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voice Evaluation
Description: Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway Reconstruction
Description: This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
Study: NCT04257448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Powder and solvent for solution for infusion; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Powder and solvent for solution for infusion; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Powder for suspension for injection; Subcutaneous use
Study: NCT00917527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
Study: NCT02556996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC/rCTB vaccine
Description: Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10\^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10\^11 heat-killed bacteria per dose)
Study: NCT02931136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huperzine A
Description: The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will treatment by the placebo in 52 weeks.
Study: NCT04427683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindful parenting program
Description: Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief mindful parenting program
Description: Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
Study: NCT00029913

Intervention type: OTHER
Intervention: Observation
Description: Observation of participants who received HIV preventive vaccine and became infected.
Study: NCT03589495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetyl L Cysteine
Description: 100 mg/kg n acetyl cysteine dissolved in dextrose5%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dextrose 5%
Study: NCT04257448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Powder for suspension for injection; Subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Powder for suspension for injection; Subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Powder for suspension for injection; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Powder for suspension for injection; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Powder for suspension for injection; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Powder for suspension for injection; Intravenous use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: Powder for suspension for injection; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Powder for solution for infusion; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Powder for solution for infusion; Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Powder for solution for infusion; Intravenous use
Study: NCT01460953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health literacy training video
Description: participants will watch a training video
Study: NCT02274181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Study: NCT03702751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive tape
Description: will be subjected to skin repair after episiotomy with skin adhesive tape.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous subcuticular skin suturing
Description: will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
Study: NCT00006392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU daily by mouth for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU daily by mouth for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 mcg daily for 7-12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 mcg daily for 7-12 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin E placebo
Description: daily for 7-12 years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E placebo
Description: daily for 7-12 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selenium placebo
Description: daily for 7-12 years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: selenium placebo
Description: daily for 7-12 years
Study: NCT02131441

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic hepatectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: open liver resection
Study: NCT03090087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
Study: NCT02902081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01063387

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer
Description: Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer
Description: Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
Study: NCT03633526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659/TEZ/IVA
Description: VX-659/TEZ/IVA FDC tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA mono tablet.
Study: NCT00943891

Intervention type: PROCEDURE
Intervention: Tumor biopsies
Study: NCT02576444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: The recommended dose will be available no earlier than March 2016.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
Study: NCT00492323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carisbamate
Description: 200 mg tablet twice daily for 4 weeks
Study: NCT04124484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
Description: One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
Description: One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
Description: Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
Description: Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
Study: NCT00865683

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA Supplements
Description: Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplements
Description: Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
Study: NCT04257448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Powder for solution for infusion; Intravenous use